ALPHAMAB ONCOLO.DL-000002 (3NK) — Financial Flexibility Index
ALPHAMAB ONCOLO.DL-000002 (3NK) has a Financial Flexibility Index of -0.23x as of December 2025. Free cash flow of €-90.30 Million (operating CF €-121.89 Million minus capex €31.59 Million) represents 0% of total liabilities (€386.17 Million). Also explore ALPHAMAB ONCOLO.DL-000002 annual equity growth to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
ALPHAMAB ONCOLO.DL-000002 Financial Flexibility Index (2021–2025)
Historical Financial Flexibility Index trend for ALPHAMAB ONCOLO.DL-000002 across 5 annual periods. Check ALPHAMAB ONCOLO.DL-000002 (3NK) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Annual Financial Flexibility Index for ALPHAMAB ONCOLO.DL-000002 (2021–2025)
Year-by-year free cash flow to debt coverage for ALPHAMAB ONCOLO.DL-000002. For the full company profile including market capitalisation, see how much is ALPHAMAB ONCOLO.DL-000002 worth.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.23x | €-90.30 Million | €-121.89 Million | €386.17 Million | ▼ -140.9% |
| 2024 | 0.57x | €234.11 Million | €212.34 Million | €409.87 Million | ▲ +259.4% |
| 2023 | -0.36x | €-166.66 Million | €-202.84 Million | €465.00 Million | ▼ -17.6% |
| 2022 | -0.30x | €-170.66 Million | €-300.31 Million | €559.86 Million | ▼ -56.6% |
| 2021 | -0.19x | €-162.48 Million | €-320.60 Million | €834.80 Million | — |